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Stereotactic radiosurgery (SRS) is an important treatment option for intracranial lesions. Many studies have shown
the effectiveness of photon-SRS for the treatment of skull base (SB) tumours; however, limited data are available for
proton-SRS.
Several photon-SRS techniques, including Gamma Knife, modified linear accelerators (Linac) and CyberKnife, have
been developed and several studies have compared treatment plan characteristics between protons and photons.
The principles of classical radiobiology are similar for protons and photons even though they differ in terms of
physical properties and interaction with matter resulting in different dose distributions.
Protons have special characteristics that allow normal tissues to be spared better than with the use of photons,
although their potential clinical superiority remains to be demonstrated.
A critical analysis of the fundamental radiobiological principles, dosimetric characteristics, clinical results, and toxicity
of proton- and photon-SRS for SB tumours is provided and discussed with an attempt of defining the advantages
and limits of each radiosurgical technique.
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The skull base (SB) forms the floor of the cranial cavity
and separates the brain from other facial structures. It is
a very complex anatomical region that includes portions
of the anterior cranial fossa, clivus, petrous bone, middle
cranial fossa, cavernous sinus and infratemporal fossa
encompassing several critical neurovascular structures.
Many histologic tumour types arise in the SB. They
are rare lesions representing a very heterogeneous group
from benign to malignant tumours.
Skull base tumours are challenging lesions because of
their anatomical location. Surgical intervention is often
the first step in therapeutic management, allowing for
pathologic analysis with complete or partial tumor re-
moval. Due to the proximity of critical normal struc-
tures, surgical intervention can result in complications* Correspondence: amichett@atrep.it
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reproduction in any medium, provided the orthat severely affect vision, hearing, speech, swallowing,
and could even be life-threatening.
New radiation therapy (RT) techniques allow targeting
SB tumours when surgery is not feasible, macroscopic
residual is left after surgical intervention or as an alter-
native, definitive treatment. Most patients with lesions of
the SB have a benign tumour and are expected to live
for an extended period. Due to the close proximity of
multiple critical normal structures, highly conformal RT
techniques are desired to achieve a steep dose fall-off at
the edge of the target volume, decreasing dose to sur-
rounding structures in order to reduce the potential
morbidity of treatment.
Recent technological advances in photon-RT have
allowed improved targeting accuracy. External beam
radiation therapy (EBRT) using conventional fractionation
delivers a total radiation dose in multiple daily sessions of
1.8 - 2 Gy, five times a week to a histology-dependent total
dose. Contemporary EBRT for SB tumors typically involves
both image-guided intensity modulated radiation
therapy (IMRT) and conventional fractionation stereotacticral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reduce dose to adjacent normal structures. Conventional
fractionation is usually reserved for lesions larger than the
ones usually treated with single fraction radiosurgery, or for
tumors abutting or compressing critical normal structures
where there is no adequate separation for single fraction
treatment. Radiosurgery options include:
1. Stereotactic radiosurgery in a single fraction (SRS):
irradiation is delivered by a single large dose with
very steep fall-off in dose outside the lesion to small
volumes in order to be tumouricidal or ablative [1],
2. Hypofractionated stereotactic radiation therapy
(HSRT): multi-session radiosurgery (two to five
sessions) delivering larger doses per fraction than
EBRT but not as large as with SRS.
Different techniques are used to deliver stereotactic
treatments, utilizing precise patient immobilization, set-
up uncertainty reduction, targeting accuracy, delivery of
high doses, and heterogeneous dose distribution with a
steep dose gradient. The tumour volume to be treated is
crucial, and some have advocated HSRT for large-
volume tumours. In these cases, target conformality and
selectivity are reduced in comparison to SRS. At present,
there are no long-term data to substantiate the role of
HSRT over SRS for appropriately-selected patients. Pre-
liminary data [2] suggest that HSRT may represent an
effective treatment associated with lower risk of
radiation-related adverse effects in patients with periop-
tic or large benign tumours as compared to SRS, al-
though potential benefits remain to be demonstrated.
For the purpose of this review, from now on our discus-
sion will focus only on SRS showing technical character-
istics and clinical results of its application.
Despite the enhancements in delivery with better
conformality indices, photons still have a relatively
high exit dose (beyond the tumour target), which can
produce significant normal-tissue exposure. Protons
have similar biological effectiveness to conventional
photon radiation but the defined range exhibited by
the Bragg peak results in an energy deposition with
no exit dose beyond the target volume. These funda-
mental physical properties enable proton RT to offer
superior dose distribution and reduced low-dose inte-
gral irradiated volume [3], allowing more radiation
dose to be delivered to the tumour while significantly
lowering the dose to the surrounding normal tissues
(Figure 1).
Protons appeared very attractive as a stereotactic radi-
ation tool mainly in their developmental phase when
many of the comparisons for the advantageous dose dis-
tributions were made against simple photon field
arrangements, which are now obsolete.Protons have a dosimetric advantage over photons,
particularly in the case of larger intracranial lesions.
However, as the smaller lesions are concerned, alterna-
tive techniques developed in the meantime, such as
Gamma Knife (GK) and linear accelerators (Linac),
appeared to be equally effective and less costly.
Considering the continuous advancement of technology
in delivering SRS with photons and the increased use of
protons, we have deemed it useful to review this issue by
evaluating differences with photons and possible advantages
of the use of protons as a radiosurgical technique.
SRS delivery systems
Photon stereotactic irradiation can be delivered with dif-
ferent machines and techniques: Cobalt-60 gamma
radiation-emitting sources introduced in clinical practice
at the end of the 60’s or Linac adapted for radiosurgical
works available from 1980.
Gamma knife
In its mostly used version, GK contains 201 small
Cobalt-60 sources of gamma rays arrayed in a hemi-
sphere within a thickly-shielded structure. A primary
collimator aims the radiation emitted by these sources
to a common focal point. A second external collimator
helmet has an array of removable tungsten circular colli-
mators of different sizes (one per source) that are used
to create different diameter fields at the focus point.
Patients are typically immobilized in a fixed frame with a
positioning accuracy <0.5 mm. The dose is typically pre-
scribed at 50 per cent to obtain the maximum dose at
the centre of each pinpointed target and minimal dose
at target edge. For large, non-spherical targets, like the
majority of SB tumours, a different combination of num-
ber, aperture and position of the collimators is used to
create a high degree of tumor conformality by develop-
ing a plan with multiple isocenters, preserving a sharp
fall-off in dose to surrounding structures while providing
conformal coverage of the irregular target.
Linac
Instead of using an array of Cobalt sources, Linac SRS
utilizes photons which are derived from colliding accel-
erated electrons with a metal target. Patients are immo-
bilized in a fixed frame (with less than 0.5-1 mm
accuracy) and the treatment is delivered through the use
of multiple arcs or beams resulting in a similar high dose
differential between the target and normal tissues. Iso-
dose gradients can be improved by the use of intensity
modulation of the beams, restriction of gantry angles
and arc lengths, microcollimation, and multiple isocen-
ters. SRS may be delivered using cones or circular colli-
mators or, more frequently, micro-multileaf collimator
(MLC). MLC consists of a computer-controlled array of
Figure 1 Dose distribution in sagittal (A), coronal (B) and axial (D) views of a left cavernous sinus benign meningioma treated by
proton radiosurgery. Tumour volume was 5.7 cubic centimetres (in red). The treatment was delivered with a dedicated radiosurgical device
(STAR). A dose of 12 cobalt gray equivalent (CGyE) was prescribed to 90 per cent isodose. Three equally weighted passive scattering beams were
employed. The dose-volume histogram graph (C) shows the doses to organs at risk (optic chiasm in sky-blue, left optic nerve in bright yellow,
brainstem in green, left cochlea in blue, pituitary gland in dark yellow) and tumour volume (in red). Courtesy of Francis H. Burr Proton Therapy
Center – Massachusetts General Hospital, Boston (USA).
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attached to the head of the Linac. The leaves of the
MLC can be moved in and out to create an adjustable
aperture through which radiation beams are directed to
the patient’s tumour. The treatment can be delivered as
fixed beams or dynamic arcs and the aperture shape can
be dynamically changed as treatment progresses. The
MLC also facilitates intensity modulated radiosurgery
(IMRS), which enables more complex dose distributions
for irregular, non spherical tumours. Using the adjust-
able leaves of an MLC a different dose intensity can be
delivered to different areas of the tumour, with the aim
to reduce the dose in areas where the beam is close to
or is passing through radiation-sensitive brain structures,
such as the optic pathways, cranial nerves, and brain-
stem (Figure 2). Radiation delivered by Linac-based SRS
is more homogeneous in dose if compared to GK andthis may represent an advantage when treating larger
tumours that include radiation-sensitive brain structures.
By contrast, GK may achieve a better conformality when
irradiating irregularly-shaped targets if compared to
Linacs [4].
Cyber knife
CyberKnife (Accuray, Sunnyvale, CA) is a relatively new
technological device which combines a mobile linear ac-
celerator mounted on a robotic arm with an image-guided
robotic system allowing for frameless SRS. Patient position
and motion are measured by two diagnostic x-ray cameras
and communicated in real time to the robotic arm for
beam targeting and patient motion tracking. Patients are
fixed in a thermoplastic mask and the treatment can be
delivered in one or few fractions achieving the same level
of targeting precision as frame-based SRS [5]. CyberKnife
Figure 2 Prescription isodose distribution in sagittal (A), coronal (B) and axial (C) views of a recurrent pituitary adenoma extending to
the parasellar region, and in close proximity of the optic chiasm (contoured in green) and the brainstem (contoured in brown). The
target volume (contoured in purple) was created by the geometric expansion of pituitary tumour plus 1 mm. The patient was treated with a
linear accelerator (LINAC) stereotactic radiosurgery (SRS) with a single dose of 18 Gy prescribed to the 95 per cent isodose line. The 90 per cent,
70 per cent and 50 per cent isodose curves showing dose levels delivered to surrounding tissues and adjacent critical structures are represented.
High-dose homogeneity and conformity was achieved with the use of intensity-modulated stereotactic radiosurgery (IMSRS), in which intensity
modulation of dose for each beam is obtained by moving the leaves in the micro multi-leaf collimator during the course of treatment (D). The
dose-volume histogram (DVH) graph indicates that doses to optic chiasm (green) and brainstem (brown) were below the tolerance generally
accepted for these stuctures (E), while delivering an homogeneus dose to the target volume (purple).
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with tumours involving the optic apparatus and patients
not suitable for radiosurgery.
Protons
Proton beams are delivered through fixed-horizontal-
beam rooms or rotational-beam rooms. A dedicated
stereotactic intracranial beam line equipment, the STAR
system [6], is located at the Massachusetts General Hos-
pital. For the treatment, patients can be positioned on
treatment couches or specific chairs and, in general, the
steps involved are very similar to those for photon-based
SRS. In order to generate the desired dose distribution,two principal categories of beam delivery systems are
used: passive systems (scattering) and dynamic systems
using scanning magnets (pencil beam scanning).
In the former system, the beam is spread out by the
means of one (single scattering) or two (double scattering)
scatterers to cover the field cross-section. The use of a
range modulator allows spreading out the Bragg peak in
depth to cover the target in that direction. Finally, better
dose conformation to the target is achieved with patient
field-specific hardware. Brass apertures shape the dose
according to the outer target boundary while a plastic
range compensator tailors the dose in depth at the ex-
pense of a certain unwanted full dose proximal to the
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produces fast neutrons that can deposit unwanted and
worrisome dose to the patient. Worldwide, proton therapy
centres with the exception of Paul Sherrer Institute (PSI)
in Villigen (SWI), have employed routinely passive scatter-
ing until recently. Currently, there are many efforts in
developing a more innovative delivery technique, pencil-
beam scanning (PBS), in which a narrow pencil beam is
magnetically deflected to paint the dose throughout the
target. PBS allows the dose conformation laterally, distally
as well as proximally to the target volume. Due to the ab-
sence of proton interactions with the aforementioned
materials the neutron dose to the patient is also mini-
mized. PBS inherently promotes the delivery of intensity-
modulated proton therapy (IMPT). In fact, the
optimization of energy and intensity of the narrow pencil
beams allows the delivery of non-homogenous dose distri-
butions for every single field. The superposition of mul-
tiple (inhomogeneous) fields delivers a very homogenous,
highly conformal treatment while best sparing organs at
risk. It is noteworthy that due to the energy-dependent
depth dose distribution IMPT introduces an additional
degree of freedom in dose modulation with respect to
photon IMRT. At the moment this innovative delivery
technique has not been applied to radiosurgical treat-
ments but could deserve further investigation especially in
case of regular and irregular shaped, medium to large
lesions.
Radiobiology of SRS
Fractionation is a key strategy in conventional radiother-
apy. The corresponding radiobiological effects provide
sparing of the normal tissues, while producing optimal
tumour damage [7]. Conversely, SRS exploits a different
pattern of dose distribution, rather than radiobiological
differences between normal and tumour tissue, to
achieve effective tumour destruction.
Experimental and clinical data suggest that the radio-
biological principles may differ when irradiation is deliv-
ered in large single doses [8] or when a different type of
radiation such as protons is employed [4].
For a comprehensive review of the radiobiological
principles of fractionation and radiosurgery, the reader is
referred to specific textbooks and articles [9-11].
An overview on the aforementioned topics is provided
as follows.
Firstly, because of their oxygen deficiency, hypoxic
cells are highly resistant to the radiation-related killing
[12]. The oxygen-related influence is quantified by the
so-called oxygen enhancement ratio (OER). Unfortu-
nately, regardless of their size, malignant tumours usu-
ally contain a certain amount of hypoxic cells.
Secondly, the dose–response relationship differs accord-
ing to the type of tissues. Those containing mainly non-cycling cells (“late reacting tissues” [13]), such as most be-
nign tumours and cerebral healthy tissues are less sensitive
to small doses per fraction than tissues containing mainly
cycling cells (“early reacting tissues” [13]), such as malig-
nant tumours.
Finally, experimental data show that cells have differ-
ent radiation sensitivities in different parts of the cell
cycle [14],
Taking such knowledge into account, the employment
of a fractionated regimen allows hypoxic cells to reestab-
lish their oxygenation state [11] so that they will be more
sensitive to a second, and subsequent, dose fraction. Dose
fractionation also spares late reacting (healthy) tissues
more than early reacting (malignant tumour) tissues [10].
Finally, it allows part of the cells to leave the resistant
phase while entering in a more sensitive phase. As an
overall result, a more effective cell killing takes place.
Conversely, by delivering high single doses, the OER is
higher so that such regimen may be disadvantageous if
the target tissue is anoxic [9], early responding, and is in
close proximity of or embedded within late responding
organs at risk [15]. Finally, the delivery of a single large
dose does not allow redistribution of cells into a more
radiosensitive phase of the cell cycle. However, the ra-
tionale for SRS is that the radiobiological effect of a sin-
gle large dose of radiation results in cell kill or loss of
cell division capability, regardless of the mitotic phase.
The advantage of fractionated regimens probably does
not apply to benign tumours considering that hypoxia
unlikely plays a significant role and both tumour cells
and surrounding normal tissues belong to the same
radiobiological type [10]. Provided that SRS dose fall-off
is steep enough to surrounding structures, the delivery
of high single dose to slow growing lesions should trans-
late into a greater rate of local tumour control, while still
offering a low rate of complications.
Protons and photons differ in terms of physical proper-
ties and interaction with matter, which ultimately translate
into different dose distribution as well as biological effect-
iveness [3]. To date, such difference has been quantified in
a 1.1 relative biological effectiveness (RBE) of protons over
photons [16]. Although a generic RBE may not reflect
slight tissue and dose dependent variations in RBE, these
variations are not clinically relevant [1]. As a consequence,
all of the above stated radiobiological principles as well as
the corresponding clinical applications keep their validity
regardless of the employed type of radiation so that there
is no difference between photon- and proton-based SRS.
However, experimental data have shown that proton
RBE values increase over the last few millimeters of the
range, ultimately leading to an increased linear energy
transfer. To take into account the uncertainties of the RBE
in the terminal 2 mm of each spread-out Bragg peak
(SOBP) during proton treatment planning, one could
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might be clinically relevant for the surrounding healthy
structures. From the radiobiological standpoint, this issue
probably represents the most relevant difference between
photon- and proton-based SRS so that it is wise to take
into account the biological effects of this high-RBE com-
ponent during the planning.Dosimetrical features of SRS
Effective radiosurgery is based on the principles of speci-
ficity and selectivity [11,17]. Precision and conformal
dose planning allow specific target irradiation with a
steep fall-off into other surrounding structures. Selectiv-
ity refers to the biological differences in the response of
different tissues.
The SRS techniques have been compared in several
plan comparison studies [18-21]. The corresponding effi-
cacy has been investigated also on the basis of the nor-
mal tissue complication probability (NTCP) and tumour
control probability (TCP) models in the attempt to set
the results also on a biological basis [20-22].
In general, the difference among photon-based SRS
techniques (GK, multi- non-coplanar arcs or shaped
beams linac treatment) are negligible [18-21] even
though GK may confer greater dose heterogeneity. Con-
versely, the modality (photons or protons) can result
more important. Target features such as size, shape and
location within the brain can influence the choice for
the best SRS modality. In fact, all modalities are equally
good if the target is small and regular [20,21].
Based on the normal brain dose, the dosimetrical ad-
vantage of charged particles relative to photons is evi-
dent in all types of target [18,20,21]. Such difference is
more relevant under the 60 per cent dose level regard-
less of the target features [20]. Moreover, the larger the
target volume the greater the difference [18,20,21],
which peaks for regular shaped targets larger than 24–
26 cc even though it can be relevant even for smaller
and irregular targets (about 6 cc) [20,21].
All of the above-stated considerations also apply with
respect to the lesion’s shape and location.
In case of photons, both GK and shaped beams Linac
fields allow for better target conformality [19,21] when
compared to standard arcs with fixed circular collima-
tors Linac treatments. A further consideration can be
made regarding the dose within the target. In fact, if the
area to be irradiated includes normal brain tissue, the
target dose homogeneity represents a further parameter
that can reduce the risk of side effects. Dosimetrical
comparisons point out that protons have an advantage
over other modalities, particularly in the case of irregular
targets [21]. However, it is unknown if greater homogen-
eity can influence tumour control rates in SRS.All of the above-mentioned quantitative differences
were confirmed when the analysis was approached on a
biological basis, being the NTCP different according to
the treatment modality, size, shape and location of the
target [20,22]. Again, protons demonstrated the lowest
NTCP for medium-large regular and irregular shaped
lesions [20,22]. In this scenario, charged particles scored
NTCP values 4–6 per cent smaller than photon
techniques.
In this context, it is noteworthy that radiation-induced
tumours were reported after photon SRS [23,24]. It is
well-known that protons feature a low integral dose to
healthy structures providing the potential to reduce this
risk. However, the tissue volume that can benefit from
this feature may be very small in SRS and the corre-
sponding clinical gain might be difficult to detect.
In conclusion, in the attempt to customize the treat-
ment according to the clinical scenario, it is possible to
state that small to medium regularly shaped lesions can
be effectively managed by all photon-based techniques
although at the expense of some target dose inhomogen-
eity. The charged particle capability to simultaneously
provide high target conformity and dose homogeneity
maximizes for regularly- and irregularly-shaped, medium
to large lesions.
Finally, it is noteworthy that despite such comparisons
included several planning and treatment strategies, fur-
ther improvements, such as IMRT and IMPT have been
introduced. These certainly deserve further investigation.
Clinical results of photon and proton SRS for skull base
tumours
Search strategy and selection criteria
Data for this review were obtained using MEDLINE
databases, which were searched for publications between
period of January 1980 and December 2011.
The search terms were: “skull base” and “stereotactic
radiosurgery”. Further search was made by adding the
definitions of different SB tumours (“meningioma”,
“schwannoma/acoustic neuroma”, “pituitary adenoma”,
“chordoma”, “chondrosarcoma”, “craniopharyngioma”,
“olfactory neuroblastoma/esthesioneuroblastoma”, “glo-
mus jugulare/chemodectoma”, and “proton”) to the
previously-searched keywords.
The search was limited to articles written in English. Edi-
torials, case reports, letters of opinion, and congress
abstracts were excluded, even if they added valuable infor-
mation. In case of repeated publications from the same in-
stitution, only the most updated was used for the analysis.
Papers of the search were reviewed and prioritized accord-
ing to content relevancy. Reference lists from these sources
were searched for additional publications. A systematic re-
view was beyond the aim of the paper; the following results
are reported in the form of a narrative synthesis.
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In total, 449 reports related to SRS for base of the skull
tumours were retrieved from the initial PubMed and
reference lists search: 261 from the first search and 188
from the following. In particular, 104 studies regarded
meningioma, 26 schwannoma/acoustic neuroma, 19 pi-
tuitary adenoma, 11 chordoma and/or chondrosarcoma,
6 craniopharyngioma, 3 olfactory neuroblastoma/esthe-
sioneuroblastoma, 7 glomus jugulare/chemodectoma.
After applying the inclusion criteria, 298 studies were
considered for this review.
SRS has been increasingly employed as primary or
post-operative treatment with more than 10,000 patients
reported in published studies over the last two decades.
Much less data is available on the treatment with
proton-SRS (nine reports) even though several types in
benign and malignant settings and also non-tumoural
lesions as arteriovenous malformations have been trea-
ted since its early use showing that this is a viable option
for larger volumes.
To date, no randomized or non-randomized study has
compared photon-SRS with proton-SRS, and almost all
the studies available in literature are retrospective.
Meningioma
The majority of meningiomas (90–95 per cent) are benign
(WHO grade I). Surgical resection is the preferred treat-
ment for easily accessible tumours that can be safely
removed. SRS has been used as an alternative to surgical re-
section for poorly accessible lesions, as a primary therapy
for benign meningiomas or recurrent tumours, and as an
adjuvant treatment for post-surgical residual lesions. The 5-
year control rate is equivalent to that of gross-total resec-
tion but with lower morbidity. Additionally, adjuvant treat-
ment of subtotally resected tumours results in local control
rates equivalent to gross-total resection [25].
Recently published multicenter series and reviews [26-
30] on benign lesions show a 5-year control rate ≥ 92 per
cent. SRS is usually reserved for locations such as the cav-
ernous sinus where surgical risk is expected to be higher
and is considered suitable for meningiomas with max-
imum diameter less than 3 to 4 cm, with distinct margin
with minimal to no surrounding oedema and with
sufficient distance from critical normal tissue to allow for
appropriate normal tissue dose restriction [29,30]. Radio-
surgical doses between 12 and 18 Gy have been used in
the control of SB meningiomas. A similar 5-year actuarial
tumour control rate in the range of 90–95 per cent has
been observed with doses of 15–16 Gy or 12–14 Gy.
However, several studies demonstrated that tumour con-
trol is decreased for superficial lesions and with increasing
tumour size [26,31,32]. In addition, radiation toxicity
increases with increasing tumour size and superficial loca-
tion. After radiosurgery, better outcomes were observedfor those receiving an optimal radiosurgery dose and har-
boring tumours located in a cerebellopontine angle, para-
sellar, or petroclival location [28].
Radiation-induced toxicity has been shown in up to 40
per cent after SRS, being represented by either transient
or permanent neurological complications; however, the
reported rate of significant complications at doses of
12–15 Gy, as currently used in most centres, is relatively
low. Kondziolka et al. [31] reported permanent neuro-
logical deficits of 6·3 per cent for cavernous sinus men-
ingiomas treated with GK SRS. Nicolato et al. [33]
showed late transient or permanent complications in 4,5
per cent of patients, and similar complication rates have
been reported in the majority of published series [28].
Other complications, as epilepsy, internal carotid occlu-
sion, and hypopituitarism have been rarely reported (less
than 1–2 per cent).
Atypical or malignant meningioma are usually irra-
diated adjuvantly after complete surgical excision. EBRT
is usually employed after surgery whereas SRS is
reserved to recurrences; the experience in this field is,
however, very limited [34].
Protons have usually been used in this context with
conventional fractionation and in association with
photons [35-37], but also with hypofractionated regi-
mens or single-session SRS [38-40]. Proton HSRT with
three or more fractions showed a local control of 91 per
cent at 5 years [38] and 100 per cent at 3 years [39]. The
group of MGH in Boston [40] has recently reported the
results of 51 cases of benign meningioma treated with
proton-SRS between 1996 and 2007 as primary treat-
ment (n = 32) or for residual tumour following surgery
(n = 8), or recurrent tumour following surgery (n = 10).
The median dose delivered was 13 Gy (RBE) (relative
biological effectiveness) (range, 10 -15·5 Gy (RBE)) pre-
scribed to the 90 per cent isodose line. After a median
follow-up of 32 months (range, 6–133 months), MRI
revealed 33 meningiomas with stable, 13 with decreased,
and five with increased size. The 3-year actuarial tumour
control rate was 94 per cent. Symptoms were improved
in 47 per cent (16/34) of patients. Potentially permanent
adverse effects after SRS were recorded in 3/51 (5·9 per
cent) patients. The main limitation of these studies is
that longer follow-up is needed to assess the durability
of tumour control.Pituitary adenoma
The role of RT in pituitary adenomas is well-established
[41] particularly when medical and surgical options have
been exhausted. Therapeutic goals when performing RT
for pituitary tumours are: 1) stopping of tumour growth
by preventing problems from mass effect and 2)
normalize excessive hormone secretion.
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ness of SRS in patients with nonfunctioning and secret-
ing pituitary adenomas have been recently reviewed
[42,43]. In 15 studies reporting 684 patients with non-
functioning adenomas treated with SRS at doses of 15–
22 Gy, the reported 5-year actuarial tumour control rate
was 94 per cent. A similar local control was observed in
patients with secreting pituitary adenomas, although
higher doses in the range of 18–26 Gy were employed
with the aim to achieve normalization of hormone
hypersecretion. SRS data for 1215 patients with acro-
megaly have been reported in 29 studies [42]. At a me-
dian follow-up of 50 months, the 5-year and 10-year
biochemical remission rates were 44 per cent (range,
15–60 per cent) and 74 per cent (range, 46–86 per cent),
respectively. Time to response ranged from 12 to 66
months. Results of SRS have been reported for 280
patients with Cushing’s disease in 12 studies [43]. At a
corrected median follow-up of 45 months, 48 per cent
of patients had biochemical remission of disease, with a
reported time to hormonal response ranging from 3
months to 3 years. SRS is rarely used in the treatment of
prolactinomas since medical treatment with dopamine
agonists can achieve tumour shrinkage and normalize
prolactin (PRL) levels in more than 80 per cent of
patients. When employed in patients who fail surgery
and medical therapy, at a median follow-up of 29
months, normalization of elevated PRL levels has been
observed in 33 per cent of 353 patients included in 18
studies, with a reported time to hormonal response ran-
ging from 5 to 40 months [43]. The reported overall rate
of serious complications after SRS is low. The main
complication is hypopituitarism which is reported in up
to 47 per cent of patients, with higher rates in those
series with a longer median follow-up.
Data on proton treatment in pituitary adenomas are
available both with the option of conventional fraction-
ation [44] and with SRS [45,46]. In a small series of 22
patients treated with proton SRS for persistent acromeg-
aly at a median follow-up of 6·3 years, the biochemical
remission of disease was observed in 13 patients (59 per
cent) [45]. Time to response was 42 (range, 6–62)
months. In a retrospective series of 33 patients with
Cushing’s disease at a median follow-up of 62 months,
normalization of plasma and urinary free cortisol was
achieved in 17 (52 per cent) patients, with a time to re-
mission of 18 (range, 5–49) months [46]. In both series
the only reported toxicity was represented by new pituit-
ary deficits which occurred in up to 52 per cent of
patients, whereas no visual complications, seizures, or
secondary tumours were noted. The small number of
cases treated and limited follow-up precludes to draw
firm conclusions. Proton-SRS may offer better dosimet-
ric coverage of the pituitary gland than photon-basedtreatments that could be particularly useful in paediatric
patients [47,48].
Acoustic neuroma/vestibular schwannoma
Acoustic neuroma is the most studied disease to which
SRS is applied as a stand alone treatment. SRS as an ef-
fective treatment for acoustic neuroma has evolved over
the last decades, leading to an improvement of local
control and reduction of long-term toxicity. At doses of
12–13 Gy, as used in most recent studies, SRS results in
an actuarial 5-year tumour control between 92 and 100
per cent with a low incidence of radiation-induced com-
plications [49]. Current evidence supports its use for
small to medium sized primary and recurrent vestibular
schwannomas. It is also recommended for adjunctive
therapy, recurrent tumours, in poor surgical candidates,
and for those who do not desire observation or surgery
[50].
The reported local control with doses of 12–13 Gy is
similar to that reported with higher doses in the range
of 15–18 Gy as used in early experiences of SRS, how-
ever with a lower incidence of radiation-induced compli-
cations. A recent review of more than 2000 patients
included in 23 studies has shown an overall facial nerve
preservation rate of 96 per cent after GK, with a signifi-
cant better facial nerve preservation rate in patients re-
ceiving ≤ 13 Gy of radiation at the marginal dose and
with a tumour volume ≤ 1·5 cm3 [51] . Using similar
doses, an overall hearing preservation, as defined by the
maintenance of Gardner-Robertson Grade I or II after
SRS, has been reported in 51 per cent (range, 32–71 per
cent) of 4234 patients included in 45 publications [52].
Equivalent tumour control and hearing preservation
rates have been reported for larger acoustic neuromas
compressing the brainstem, with a reported balance im-
provement or stabilization in more than 85 per cent of
patients who had imbalance at presentation [53]. Neuro-
logical toxicity, including facial and trigeminal neuropa-
thies, and balance disturbances may occur in 0–3 per
cent of patients. Hydrocephalus has been observed in 1–
2 per cent of patients, whereas radiation-induced
tumours or malignant transformation of acoustic neur-
oma have been reported rarely [50-54].
Also in this site, proton beam has been used with con-
ventional fractionation [55] or with SRS with a satisfac-
tory level of hearing, facial nerve, trigeminal nerve
preservation, and with tumour control rates of 84–100
per cent [56-58] . Weber et al. reported on 88 patients
treated at the MGH between 1992 and 2000 with
proton-SRS [56]. At a median follow-up period of 38,7
(range, 12–102) months the actuarial 2- and 5-year
tumour control was 95,3 per cent and 93·6 per cent, re-
spectively. Hearing was preserved in 33 per cent of 21
(24 per cent of the total) patients with functional hearing
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geminal nerve function preservation rates were 91 per
cent and 89 per cent, respectively. Three patients (3,4
per cent) underwent shunting for hydrocephalus.
HSRT with a dose of 26 Gy (RBE) in three fractions
was delivered with protons in the study of Verminnen
et al. [58]. At a median follow-up of 72 months, the 5-
year local control was 98 per cent.
Craniopharyngioma
The treatment of craniopharyngioma is based on a surgical
treatment with transcranial approaches or endoscopic
endonasal surgery followed by RT, mainly in form of frac-
tionated regimens with a local control of 80–90 per cent at
5–10 years [59]. The proximity of craniopharyngiomas to
the optic pathways provides a major limitation to the use of
SRS, although in very selected series of relatively small re-
sidual tumours, a local control rate between 34 and 88 per
cent has been reported [60-62]. Tumour control was
achieved with a median dose of 22–24 Gy (marginal dose
11–12 Gy), whereas the use of lower radiation dose results
in an unsatisfactory tumour control [63]. The reported late
toxicity after SRS ranges from 0 to 38 per cent, mainly
represented by visual and endocrinological deficits [59]. In
general, treatment of craniopharyngiomas with SRS is not
considered a standard procedure.
Protons have been recently used for the treatment of
this tumour but only with fractionated regimens [64],
and to date no experience with proton SRS has been
reported.
Chordoma – chondrosarcoma
Nowadays, the improvements in surgical techniques
allow more radical resection of these tumours, while fre-
quently providing small residual lesions, which can be
suitable for SRS. Again, very few clinical data have been
published on this issue with promising preliminary
results showing that SRS at marginal doses of 14–16 Gy
could represent a valuable treatment option for small-
sized chordomas residual after surgery or relapsing [65-
68].
Data on this issue are limited and SRS cannot be con-
sidered a standard form of treatment for these tumours.
Protons have been used only with conventional frac-
tionation at doses ≥ 70 Gy both in chordoma and chon-
drosarcoma, even of large volume, with very satisfying
results independently by their size [69,70].
No data are available at this moment with the use of
proton-SRS.
Chemodectoma/glomus jugulare tumours
Radiation has been found to be helpful in controlling
glomus jugulare tumour growth by inducing fibrosis
around the supplying vessels. In 2011, a comprehensivesearch of the English-language literature identified 109
studies that collectively described outcomes for patients
with glomus jugulare tumours [71]. Data collected from
869 patients were assessed. Patients undergoing SRS had
the lowest rates of recurrence and the most favourable
rates of tumour control. In particular, those treated with
subtotal resection plus SRS had a control rate of 71 per
cent at 96 months of follow-up. Patients undergoing SRS
alone at a median follow-up of 71 months had a tumour
control rate of 95 per cent. A recent meta-analysis [72]
was published on these tumours treated with SRS. The
data search yielded 19 studies. Across all studies, 97 per
cent of patients achieved tumour control, and 95 per
cent of patients achieved clinical control suggesting con-
sidering SRS for the primary management of glomus
jugulare tumours. Average marginal dose in Gy delivered
was between 12 and 20.4 Gy (median 15 Gy, mean
15.17). In particular, SRS can be considered a safe and
effective treatment for patients with preserved glosso-
pharyngeal and vagus nerve function, after surgical re-
currence, in the elderly, and in patients with serious
preexisting medical conditions [73].
Again, no data are available for the use of proton-SRS
in this field.Olfactory neuroblastoma/esthesioneuroblastoma
Olfactory neuroblastoma or esthesioneuroblastoma is a
rare tumour of the frontal SB still associated with high
rates of tumour recurrence and mortality. A meta-
analysis by Dulguerov and colleagues [74] demonstrated
that surgery with radiation is the most frequently used
therapeutic approach, and the one achieving the highest
cure rates. Also, in this disease SRS cannot be consid-
ered standard of care. The data in literature is scarce:
radiosurgery can be considered in combination with
endoscopic sinus surgery as a promising treatment op-
tion [75,76].Conclusions
Stereotactic radiosurgery is an increasingly-used treat-
ment option supported by extensive number of studies in
the management of SB tumours. Current data show excel-
lent results in treating several tumours of the SB includ-
ing meningioma, pituitary adenoma and vestibular
schwannoma. Long-term data indicate a tumour control
in more than 90 per cent of cases after 5 and 10 years,
with an acceptable incidence of complications. Favourable
data with the use of SRS are reported also for other rare
tumours such as craniopharyngioma, chordoma, olfactory
neuroblastoma and glomus jugulare tumour. Further
studies are needed in order to fully elucidate its role in
these lesions while considering the high risk of radiation
injury to tissues.
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cal technique although the reported outcome is similar
for patients with SB tumours treated with other photon
techniques.
Even though proton therapy is increasingly used in the
clinical community, only few studies have been per-
formed to assess the efficacy and toxicity of proton-SRS
in SB tumours. The number of institutions that are cur-
rently using protons is still small, particularly those per-
forming proton-based stereotactic techniques.
Proton beam, while utilizing a different form of radi-
ation, also represents a similarly highly focused and tar-
geted radiation tool. Even though the physical properties
of protons could offer superior conformality in dose dis-
tribution with respect to photons, current clinical results
show a similar control for such tumours because similar
doses were used across photon and proton experiences.
Proton SRS has been advocated as preferred treatment
of larger and more complex SB lesions. Current data do
not allow any definitive conclusion about their presumed
superiority over other photon-based SRS techniques
mainly because of the limited number of patients treated
with protons. This makes it difficult to compare the
results. In respect to the small number of patients trea-
ted with proton SRS and short follow-up, toxicity was
similar with the use of the different techniques; however,
the evaluation of complications is often completely sub-
jective and unsatisfactory. It is important to emphasize
that protons were used with the aim to minimize normal
tissue toxicity rather than increase local control. The dif-
ference between techniques may be quite small and large
numbers of patients, followed for long periods of time,
would be needed in order to demonstrate any clinically
significant advantage. However, given the still-high costs
of protons [77], comparative multi-institutional trials are
needed to select the appropriate modality for each
tumour type.
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